Forte Biosciences Inc
NASDAQ:FBRX
Forte Biosciences Inc
NASDAQ:FBRX
Price:
24.86
USD
-4.02%
Market Cap:
$311.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Forte Biosciences Inc
NASDAQ:FBRX
|
US |
|
T
|
Tangshan Sunfar Silicon Industries Co Ltd
SSE:603938
|
CN |
|
Argosy Minerals Ltd
ASX:AGY
|
AU |
|
Emkay Global Financial Services Ltd
NSE:EMKAY
|
IN |
|
Lithium Australia NL
ASX:LIT
|
AU |
|
N
|
National Healthcare Corp
XBER:HTW
|
US |
|
E
|
Eva Precision Industrial Holdings Ltd
HKEX:838
|
HK |
|
V
|
Vishay Precision Group Inc
NYSE:VPG
|
US |
|
Thermon Group Holdings Inc
NYSE:THR
|
US |
|
Comms Group Ltd
ASX:CCG
|
AU |
|
I
|
Intouch Insight Ltd
OTC:INXSF
|
CA |
|
H
|
Havila Kystruten AS
OSE:HKY
|
NO |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of FBRX.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FBRX
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
FBRX Competitors Multiples
Forte Biosciences Inc Competitors
Forte Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
311.3m USD | 0 | -6 | -4.1 | -4.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.1B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.1B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.2B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
